Peter Mayser

Prof. Dr. Peter Mayser

orcid

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2002 in British Journal of Nutrition
Verified
Journal Article
Open access
PDF file
PMPeter Mayser
Peter Mayser
HGH. Grimm
H. Grimm
FGF. Grimminger
F. Grimminger
N-3 Fatty acids in psoriasis - Volume 87 Issue S1 - P. Mayser, H. Grimm, F. Grimminger

5 April 2002 in Archives of Dermatological Research
Verified
Journal Article
Closed access
PDF file
PMPeter Mayser
Peter Mayser
USUte Schäfer
Ute Schäfer
HKHans-Joachim Krämer
Hans-Joachim Krämer
BIBernhard Irlinger
Bernhard Irlinger
WSWolfgang Steglich
Wolfgang Steglich

1 May 2002 in Journal of Parenteral and Enteral Nutrition
Verified
Journal Article
Closed access
PMPeter Mayser
Peter Mayser
KMK Mayer
K Mayer
MMM Mahloudjian
M Mahloudjian
SBS Benzing
S Benzing
HKHj Kramer
Hj Kramer
FGF Grimminger
F Grimminger

1 June 2009 in American Journal of Clinical Dermatology
Verified
Journal Article
Closed access
PDF file
PMPeter Mayser
Peter Mayser
VFViviane Freund
Viviane Freund
DBDebby Budihardja
Debby Budihardja

1 June 2006 in Skin Pharmacology and Physiology
Verified
Journal Article
Closed access
PMPeter Mayser
Peter Mayser
JKJörg Kupfer
Jörg Kupfer
DNDiana Nemetz
Diana Nemetz
USUte Schäfer
Ute Schäfer
MNMartin Nilles
Martin Nilles
UGUwe Gieler
Uwe Gieler
In atopic dermatitis, microbial allergens may be pathogenetically significant. Apart from Staphyloccocus aureus, these are primarily lipophilic Malassezia yeasts. They are particularly involved in the pathogenesis of head and neck dermatitis (HND), a special form of atopic dermatitis, which is often difficult to treat. Fifty patients (21 men, 29 women) with moderate to severe HND of at least 6 months’ duration were included in a prospective double-blind study. All of them showed at least 10% involvement of the head-neck region. The severity of disease was evaluated by Investigator Global Assessment (IGA), Eczema Area and Severity Index (EASI) for the head-neck region and a pruritus score. IgE antibodies to Malassezia sympodialis and/or Malassezia furfur (at least CAP class 1) were a prerequisite for study enrollment. Either 1% ciclopiroxolamine cream (Batrafen; Aventis Pharma, Bad Soden, Germany) or the corresponding base cream were thinly applied to the affected areas twice daily for 28 days. Sixteen patients in the ciclopiroxolamine group and 13 patients in the placebo group completed the study. To assess the change in severity of atopic eczema, IGA differences between the individual measuring points were determined for all patients. There were significant differences in the IGA score change between the ciclopiroxolamine group and the placebo group, from t3 to t4, and over the total period. Similar, but not significant, changes were observed with the EASI score, in terms of affected skin area and itching. The present study is the first to examine the effect of antifungal single-drug therapy with a cream containing ciclopiroxolamine on the course of HND. The study medication was found to be significantly effective. To optimize this effect, suitable patients selected in terms of fungal load, specific IgE, prick test and particularly atopy patch test for Malassezia antigens could receive combined treatment with antimycotic-containing shampoos and/ or short-term systemic antimycotic therapy in severe cases.

30 March 2017 in Mycoses
Verified
Journal Article
Open access
PDF file
PNP. Nenoff
P. Nenoff
DKD. Koch
D. Koch
CKC. Krüger
C. Krüger
CDC. Drechsel
C. Drechsel
PMPeter Mayser
Peter Mayser
Summary: Miconazole is a broad‐spectrum antifungal used in topical preparations. In the present investigation the minimal inhibitory concentration (MIC) of miconazole for eighty wild type strains of gram‐positive and gram‐negative bacteria isolated from infected skin lesions was assessed using a modified agar dilution test (adapted to CLSI, Clinical Laboratory Standards Institute). 14 ATCC reference strains served as controls. Miconazole was found efficacious against gram‐positive aerobic bacteria (n=62 species), the MICs against Staphylococcus (S.) aureus, S. spp., Streptococcus spp. und Enterococcus spp. ranged between 0.78 and 6.25 μg/mL. Interestingly, there were no differences in susceptibility between methicillin‐susceptible (MSSA, 3) methicillin‐resistant (MRSA, 6) and fusidic acid‐resistant (FRSA, 2) S. aureus isolates. Strains of Streptococcus pyogenes (A‐streptococci) (8) were found to be slightly more sensitive (0.78‐1.563 μg/mL), while for gram‐negative bacteria, no efficacy was found within the concentrations tested (MIC >200 μg/mL). In conclusion, for the gram‐positive aerobic bacteria the MICs of miconazole were found within a range which is much lower than the concentration of miconazole used in topical preparations (2%). Thus topically applied miconazole might be a therapeutic option in skin infections especially caused by gram‐positive bacteria even by those strains which are resistant to antibiotics.